Cosmeceutical Formulation Development: Drug vs Cosmetic

Why Cosmeceutical Formulation Development Is Harder Than Standard Cosmetics

A standard cosmetic is built around sensory performance, physical stability, and safety in everyday use. A cosmeceutical adds a biologically active ingredient and, with it, a promise that the product changes how skin behaves. That promise raises the bar on three fronts: the active must stay potent, reach the right skin layer, and support a defensible claim. Missing any one produces a product that looks premium and underperforms.

• Potency has to be maintained, not just appearance — a cosmetic can pass stability by looking and smelling unchanged, while a cosmeceutical also needs its active content to hold up.
• Delivery becomes a design variable — the vehicle, pH, and carrier system decide how much active leaves the formula and enters the outer skin.
• Claims carry regulatory weight — the wording chosen for marketing moves a product from cosmetic to drug status in one market while leaving it untouched in another.
• Two skill sets are required — cosmetic sensory engineering and pharmaceutical-style analytical and quality discipline rarely sit in the same team.

The first decision in any project is therefore not the active or the base but the legal category the product is aiming for. Broader formulation context is available across our cosmetics and personal care and pharmaceutical and healthcare knowledge bases.

“Cosmeceutical” Is a Marketing Term, Not a Legal Category

No major regulator recognizes a legal category called cosmeceutical. The US Food and Drug Administration states that the FD&C Act does not recognize the term and that a product can be a drug, a cosmetic, or both. Classification follows intended use, which regulators read from label claims, advertising, consumer perception, and whether an ingredient has a well-known therapeutic use. Each market reaches its own answer, so one formula can be a cosmetic in Europe and an OTC drug in the United States.

• United States — the FD&C Act treats products intended to treat or prevent disease, or to affect the structure or function of the body, as drugs. Products that meet both the drug and cosmetic definitions, such as antidandruff shampoos and moisturizers with sun-protection claims, must comply with the requirements for both.
• European Union — Regulation (EC) No 1223/2009 covers products applied to external body parts to clean, perfume, change appearance, protect, keep in good condition, or correct body odor. A product presented as treating or preventing disease, or acting through a pharmacological, immunological, or metabolic action, falls under medicinal product law instead.
• India — the Drugs and Cosmetics Act, 1940 and the Cosmetics Rules, 2020 define drugs and cosmetics separately. A substance intended to affect the structure or function of the body falls within the drug definition.
• Japan and South Korea — both run an intermediate category, with regulatory review of claims such as whitening or wrinkle improvement: quasi-drugs in Japan and functional cosmetics in South Korea.

This table shows why classification has to be settled before the formula is finalized: it fixes the manufacturing standard, stability program, and evidence package the project must budget for. Specialists offering cosmeceutical regulatory classification support map each intended claim to the category it triggers in every target market before formulation begins. For the cosmetic side of these obligations, including MoCRA registration and the EU responsible-person and safety-report duties, see our guide to cosmetic regulatory pathways. The next question is how claims, rather than ingredients alone, push a product across the line.

How Claims Decide Cosmetic or Drug Status

Claims are the most direct evidence of a product's intended use, so the words on the pack and in the marketing weigh heavily in classification. FDA reads the label, advertising, website copy, and consumer expectations together, and the EU applies a similar test based on how the product is presented. One sentence promising to rebuild skin structure can reclassify an entire product line. A claims map therefore belongs before the first bench trial, not after the last.

• Appearance language — phrases such as “smoother-looking skin,” “visibly brighter,” and “hydrates” stay within cosmetic territory in both the US and the EU.
• Structure or function language — promises to rebuild collagen or regrow hair describe a change to the body itself and point toward drug status in the United States.
• Disease or condition language — phrases such as “treats eczema” are therapeutic claims and point toward drug or medicinal product status in both regions.
• Protection language — sun protection is an OTC drug claim in the United States and a cosmetic claim in the European Union, the clearest example of classification varying by market.
• Ingredient positioning — presenting an ingredient with a well-known therapeutic use in a way that implies treatment establishes drug intended use on its own.

When a claim does place a product in both categories, the manufacturing and testing burden changes in specific, predictable ways, which the next section sets out.

OTC Drug Cosmetic Hybrid Formulation: When Both Rulebooks Apply

A hybrid product must satisfy cosmetic and drug requirements at the same time, and the drug requirements set the manufacturing and testing standard. In the United States, the drug side brings current good manufacturing practice under 21 CFR Parts 210 and 211, establishment registration, drug listing, and Drug Facts labeling. The active ingredient must also be one that the applicable monograph permits for the stated use. The formula is still judged as a cosmetic for feel, appearance, and consumer acceptance, so the project carries both sets of demands.

1. Active identity and grade — the active meets the pharmacopeial standard where one exists, and supplier qualification follows drug rules.
2. Validated potency assay — a stability-indicating method, typically HPLC, validated to ICH Q2 principles, confirms the active stays within specification through expiry.
3. Stability-supported expiration date — US drug regulations require a written stability program that supports the labeled expiration date.
4. Process control and batch records — mixing order, temperatures, and hold times are documented and controlled for every batch.
5. Drug labeling — a Drug Facts panel states the active ingredient, purpose, uses, and warnings in the mandated format.

The practical consequence is that a hybrid product needs a manufacturing partner qualified for drug GMP, not only for cosmetic GMP such as ISO 22716. That makes partner selection, covered later, one of the most consequential decisions after classification. First, though, the choice of active determines what the formulation has to defend against.

Choosing Pharmaceutical-Grade Actives for Cosmetic Bases

Active selection sets both the scientific credibility and the stability burden of the whole product. Each popular cosmeceutical active carries a specific chemical weakness that the formulation must engineer around. That weakness, not the active's marketing appeal, dictates the vehicle, the pH, and the packaging. Comparing the main classes side by side shows why no universal cosmeceutical base exists.

Deeper treatment of the most demanding classes is available in our guides to retinoid encapsulation and vitamin A stabilization, vitamin C and E antioxidant systems, and niacinamide stability and pH compatibility. In cosmeceutical formulation development, the active's weakness, not its popularity, drives the design brief. Companies seeking pharma-grade active cosmetic product development services should expect a partner to work from that principle.

A stable active is only half of the job, because the vehicle must also carry it to the place where it works.

Skin Delivery Engineering for Cosmeceutical Actives

The outer skin layer exists to keep foreign molecules out, and that barrier is the central obstacle for any cosmeceutical active. The stratum corneum is a thin, lipid-rich barrier typically measured in tens of micrometers, and most molecules cross it by passive diffusion. Molecular size, lipophilicity, and ionization state all influence how easily an active crosses it, and the vehicle raises or lowers that rate. A formulator therefore designs delivery deliberately instead of assuming that a good active in a good cream reaches its target.

• Molecular size — small molecules diffuse far more readily, and a long-cited rule of thumb puts efficient passive penetration below roughly 500 daltons, which excludes proteins and many peptides.
• Lipophilicity — actives with a balance of oil and water affinity partition into and through barrier lipids better than very hydrophilic or very lipophilic ones.
• Ionization and pH — the unionized form of a weak acid or base crosses the barrier more readily, so pH relative to pKa governs delivery and irritation.
• Vehicle and thermodynamic activity — solvent choice, hydration, and occlusion change how strongly the active is driven out of the formula and into the skin.
• Penetration enhancers — solvents such as propylene glycol and fatty acids such as oleic acid temporarily disturb barrier lipid organization, at the price of added irritation risk.

Together these variables explain why the same active performs differently in a serum, a cream, and a gel. Base selection for creams, gels, and ointments, including how rheology and phase structure affect release, is covered in our guide to topical semisolid formulation.

Carrier Systems: Protecting the Active and Controlling Release

Carrier systems solve two problems at once. They shield a fragile active from oxygen, light, and water in the jar, and they control how quickly it is released on the skin. The right choice depends on the active's solubility and on the sensory profile of the finished product. Every option adds cost and process complexity, so the table below compares the trade-offs.

Carrier systems built from nanoscale particles need a regulatory check. Nanomaterials are defined as insoluble or biopersistent, intentionally manufactured materials with dimensions in the 1 to 100 nanometer range. Under Article 16 of Regulation (EC) No 1223/2009 they require notification to the European Commission before launch, with exceptions for those already regulated as colorants, UV filters, and preservatives. Each candidate carrier needs an individual assessment against that definition.

Delivery engineering also changes the safety question. The EU safety assessment divides a no-observed-adverse-effect level by the systemic exposure calculated from dermal absorption data. The result is the margin of safety, so a better-penetrating system needs its absorption measured, not assumed. A cosmeceutical active delivery consultant can run these delivery studies against the specific vehicle and set the study design before the claim is fixed. A delivery system that works on day one still has to survive the shelf life, which is where many active-rich formulas fail.

Stability, Preservation, and Packaging for Active-Rich Formulas

Active-rich formulas fail in ways that ordinary cosmetics do not. A base can stay smooth and fragrant while the active loses potency, and only a validated assay reveals the loss. Stability work for a cosmeceutical therefore tracks the active's content alongside the usual physical checks. Packaging becomes part of the formulation, because oxygen, light, and container interactions attack the active directly.

• Physical stability — viscosity, pH, droplet size, color, odor, and phase separation are tracked at controlled temperatures, through freeze-thaw cycles, and under light exposure. Our guide to cosmetic stability and accelerated aging covers the design of these studies.
• Chemical stability — a stability-indicating method measures the active and its known degradants across storage conditions. ICH Q1A(R2) is the reference framework for conditions and duration in pharmaceutical stability programs.
• Microbiological stability — preservative efficacy testing, such as ISO 11930 for cosmetics and USP <51> for pharmaceutical products, confirms the final formula in its final pack resists contamination. Low-pH actives narrow the choice of preservatives, because preservative activity depends on pH.
• Container-closure compatibility — airless pumps, aluminum tubes, and opaque or amber glass protect oxygen- and light-sensitive actives, while some actives adsorb onto or migrate into plastic components. See our article on packaging compatibility for the mechanisms.

When evaluating an active ingredient stability cosmeceutical manufacturer, ask to see its assay validation records and its stability data on comparable active-rich formulas. Stable and well delivered is still not enough, because the product has to be shown to work and to be safe.

Safety and Efficacy Substantiation for Cosmeceutical Claims

Every claim on a cosmeceutical pack needs evidence that matches its strength. The EU common criteria under Regulation (EU) No 655/2013 require cosmetic claims to be legally compliant, truthful, supported by evidence, honest, fair, and supportive of informed decisions. Potent actives make the safety side equally demanding, since irritation is a well-documented side effect of retinoids and hydroxy acids. A structured evidence ladder keeps the cost proportionate to the claim.

1. In vitro delivery studies — diffusion-cell experiments measure how much active leaves the vehicle and crosses skin or a membrane. OECD Test Guideline 428 describes the in vitro method for skin absorption.
2. Safety testing on the finished formula — human repeat insult patch testing evaluates irritation and sensitization. In the EU, a qualified safety assessor documents the result in a cosmetic product safety report.
3. Instrumental efficacy measurement — corneometry tracks hydration, transepidermal water loss tracks barrier function, colorimetry tracks pigmentation, and skin imaging tracks wrinkles and texture.
4. Blinded, vehicle-controlled studies — where the claim is strong, a controlled design separates the effect of the active from the effect of the base.

Method selection and claim wording are covered in depth in our article on clinical efficacy testing for cosmetic claims. With the evidence plan defined, the remaining task is to sequence all of this into a program and choose who executes it.

Building a Development Program and Choosing a Partner

A dependable cosmeceutical formulation development program runs as a sequence of gates, and each gate closes off a class of late, expensive failure. Regulatory intent comes first because it fixes every later standard. Delivery, stability, and substantiation follow in an order that lets early bench data shape the claim, not the reverse. The same discipline applies when a brand outsources the work or buys through private label cosmeceuticals routes.

1. Claims and classification map — define target markets, intended claims, and the resulting legal category before formulating.
2. Active and grade selection — choose the active for the claim and the market, confirming permitted status and pharmacopeial grade where required. Permitted status shifts over time. Regulation (EU) 2024/996 added concentration limits and a warning label for vitamin A derivatives in cosmetics, applying to new products from November 2025 and to existing ones from November 2027.
3. Vehicle and delivery design — set pH, solvent system, and carrier around the active's chemistry, with in vitro delivery data gathered early.
4. Stability with a potency assay — start real-time and accelerated programs on a near-final formula, with a validated method in place before the first sample pull.
5. Safety and efficacy substantiation — match the study design to the strength of the claim.
6. Scale-up and technology transfer — control oxygen exposure, temperature, and order of addition at production scale, and confirm the plant runs the GMP standard the classification requires.

Partner selection then decides whether the plan is executed as designed. A cosmeceutical contract formulation partner should be able to answer a short set of direct questions before any agreement is signed.

• GMP standard — is the site audited to ISO 22716 for cosmetics, or to pharmaceutical GMP such as 21 CFR Part 211 or Schedule M in India?
• Analytical capability — does the partner have validated HPLC capability for potency and stability testing, in-house or through a qualified laboratory?
• Regulatory support — can the partner map claims to classification in each target market, or is separate regulatory counsel needed?
• Ownership — who owns the formulation and the technology-transfer documentation when the project ends?
• Consistency — how does the partner demonstrate batch-to-batch consistency for active-rich formulas?

Our guides to choosing a pharmaceutical formulation consultant and choosing a cosmetic formulation consultant expand on these selection criteria. Global Formulation provides pharma-grade active cosmetic product development services, cosmeceutical regulatory classification support, and scale-up partnership, taking a concept from claims map through stability-verified, market-ready product.